iRadimed (NASDAQ:IRMD) CEO Sells $509,200.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $101.84, for a total value of $509,200.00. Following the sale, the chief executive officer directly owned 2,267,500 shares in the company, valued at approximately $230,922,200. This represents a 0.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

iRadimed Stock Up 0.2%

Shares of IRMD traded up $0.24 on Wednesday, hitting $103.22. The company’s stock had a trading volume of 94,257 shares, compared to its average volume of 83,352. The firm’s fifty day moving average price is $95.10 and its 200-day moving average price is $79.07. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $104.04. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of 62.56 and a beta of 1.09.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, topping the consensus estimate of $0.43 by $0.04. The firm had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, equities analysts predict that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The business also recently announced a special dividend, which was paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th were paid a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s dividend payout ratio is presently 41.21%.

Hedge Funds Weigh In On iRadimed

A number of hedge funds have recently added to or reduced their stakes in IRMD. CWM LLC lifted its position in shares of iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 211 shares during the period. Quarry LP acquired a new position in iRadimed in the third quarter valued at about $40,000. Tower Research Capital LLC TRC lifted its position in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the period. State of Alaska Department of Revenue bought a new stake in iRadimed during the third quarter worth about $47,000. Finally, Spire Wealth Management acquired a new stake in iRadimed during the second quarter worth about $60,000. Institutional investors own 92.34% of the company’s stock.

Analysts Set New Price Targets

IRMD has been the subject of several recent research reports. Zacks Research raised iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Roth Capital set a $90.00 price target on shares of iRadimed in a report on Friday, October 31st. Finally, Lake Street Capital restated a “buy” rating and set a $100.00 price objective on shares of iRadimed in a research report on Monday, November 3rd. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.33.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.